TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38846711

Group type: EXPERIMENTAL
Intervention: Glucose-lowering medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38846755

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 38846918

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 264

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 264
Study: 38847087

Group type: EXPERIMENTAL
Intervention: Nivolumab ± tadalafil
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Nivolumab ± BMS986205
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Durvalumab ± metformin
Number of subjects: 113
Study: 38847097

Group type: EXPERIMENTAL
Intervention: MAP of 77 mm Hg
Number of subjects: 134

Group type: COMPARATOR
Intervention: MAP of 63 mm Hg
Number of subjects: 134
Study: 38847281

Group type: EXPERIMENTAL
Intervention: Tenofovir-lamivudine-dolutegravir
Number of subjects: 2832

Group type: COMPARATOR
Intervention: Control group (non-switching)
Number of subjects: 2832
Study: 38847412

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rocuronium 0.9 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg/kg
Number of subjects: 50
Study: 38847460

Group type: EXPERIMENTAL
Intervention: Survodutide 2.4 mg
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Survodutide 4.8 mg
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Survodutide 6.0 mg
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study: 38847538

Group type: EXPERIMENTAL
Intervention: Intestinal colonization by carbapenem-resistant Gram-negative bacteria (CR-GNB)
Number of subjects: 4641

Group type: EXPERIMENTAL
Intervention: Carbapenem-resistant Gram-negative bacteria (CR-GNB)
Number of subjects: 4641
Study: 38847615

Group type: EXPERIMENTAL
Intervention: MBI-guided biopsy
Number of subjects: 21
Study: 38847658

Group type: EXPERIMENTAL
Intervention: 12-hole clock model
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard multimedia learning
Number of subjects: 43
Study: 38847714

Group type: EXPERIMENTAL
Intervention: Otago exercise program (OEP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gaze stability exercises (GSE)
Number of subjects: 30
Study: 38847771

Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage and autotransfusion (IBSA)
Number of subjects: 6525
Study: 38847766

Group type: EXPERIMENTAL
Intervention: Emergency surgical management of complicated colorectal cancer
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Management strategies for elderly patients with obstructed or perforated colorectal cancer
Number of subjects: 240
Study: 38847929

Group type: EXPERIMENTAL
Intervention: Group-A (MAF + biocomplex of autologous clinical-grade alveolar bone-marrow mesenchymal stem cells in collagen scaffolds enriched with aFPL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Group-B (MAF + collagen scaffolds enriched with aFPL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Group-C (MAF surgery alone)
Number of subjects: 27
Study: 38847979

Group type: EXPERIMENTAL
Intervention: Subcision with suction
Number of subjects: 154

Group type: COMPARATOR
Intervention: Subcision alone
Number of subjects: 154
Study: 38848065

Group type: EXPERIMENTAL
Intervention: Clinician-facing preventive care reminders, electronic health record-integrated shared decision-making tool, narrative LCS guidance in LDCT ordering screen (Period 1)
Number of subjects: 1865

Group type: EXPERIMENTAL
Intervention: Patient-facing reminders for LCS discussion and LCS (Period 2)
Number of subjects: 1865

Group type: COMPARATOR
Intervention: Baseline period (Control)
Number of subjects: 1865

Group type: EXPERIMENTAL
Intervention: Period 2 (Post-intervention)
Number of subjects: 1865
Study: 38848067

Group type: EXPERIMENTAL
Intervention: Extended telephone coaching (12 calls during weeks 5-16)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Brief telephone coaching (3 calls during weeks 5-8)
Number of subjects: 437

Group type: COMPARATOR
Intervention: No coaching (control)
Number of subjects: 437
Study: 38848312

Group type: EXPERIMENTAL
Intervention: Bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2)
Number of subjects: 172
Study: 38848380

Group type: EXPERIMENTAL
Intervention: Pharmacist-led interprofessional medication adherence program (IMAP) for 12 months
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care plus electronic monitors (EM) without intervention
Number of subjects: 118
Study: 38848400

Group type: EXPERIMENTAL
Intervention: Couples Health CoOp Plus (CHC+) intervention
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Stigma awareness and education workshop
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: CHC+ and stigma awareness workshop interaction
Number of subjects: 480
Study: 38848477

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-ritonavir (NMV/r, 300 mg and 100 mg)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo-ritonavir (PBO/r)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-ritonavir (NMV/r)
Number of subjects: 155
Study: 38848522

Group type: EXPERIMENTAL
Intervention: Oral cetirizine
Number of subjects: 395

Group type: COMPARATOR
Intervention: Intravenous clemastine
Number of subjects: 395
Study: 38848521

Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Serial cfDNA monitoring
Number of subjects: 12
Study: 38848537

Group type: EXPERIMENTAL
Intervention: NGS-based classifier for T-ALL
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: NGS-based classifier combined with WBC count and MRD
Number of subjects: 440
Study: 38848557

Group type: EXPERIMENTAL
Intervention: Smartphone-based morning and evening messages based on current readiness to quit smoking.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group received 2 daily messages unrelated to smoking.
Number of subjects: 152
Study: 38848742

Group type: EXPERIMENTAL
Intervention: MesoPher (dendritic cells loaded with allogeneic tumour cell lysate)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: MesoPher
Number of subjects: 176

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 176
Study: 38849054

Group type: EXPERIMENTAL
Intervention: Repeated low-level red light therapy (RLRL) plus single-vision spectacles
Number of subjects: 192

Group type: COMPARATOR
Intervention: Single-vision spectacles (control)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Repeated low-level red light therapy (RLRL)
Number of subjects: 192
Study: 38849152

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg two times per day or equivalent weight-based doses
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 225
Study: 38849283

Group type: EXPERIMENTAL
Intervention: Nivolumab plus pomalidomide/dexamethasone (NPd)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Nivolumab, pomalidomide/dexamethasone, and elotuzumab (NE-Pd)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Pomalidomide/dexamethasone (Pd)
Number of subjects: 300
Study: 38849344

Group type: EXPERIMENTAL
Intervention: Amp1q
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Gain1q
Number of subjects: 400

Group type: COMPARATOR
Intervention: Normal 1q
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone plus autologous stem cell transplantation
Number of subjects: 400
Study: 38849604

Group type: EXPERIMENTAL
Intervention: Dietary modifications to increase protein intake
Number of subjects: 26
Study: 38849605

Group type: EXPERIMENTAL
Intervention: Individualized PEEP strategy alongside extended lung protection
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 76
Study: 38849726

Group type: EXPERIMENTAL
Intervention: Ex vivo tumor-derived models (PDTO, ADS, and explants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy and PARP inhibitors
Number of subjects: 0
Study: 38849734

Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen 800 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 100
Study: 38849741

Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-FAPI-46 PET/CT
Number of subjects: 50
Study: 38849770

Group type: EXPERIMENTAL
Intervention: High nodal burden group
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: MultiP model based on PET-based radiomics
Number of subjects: 124
Study: 38849782

Group type: EXPERIMENTAL
Intervention: Good School Toolkit-Primary intervention
Number of subjects: 1910
Study: 38849829

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily for 12 months
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 38849875

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg capsule 1-2 hours before surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38849905

Group type: EXPERIMENTAL
Intervention: cfDNA-based assay
Number of subjects: 249
Study: 38849943

Group type: EXPERIMENTAL
Intervention: Lomustine (110 mg/m2)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Lomustine with reirradiation
Number of subjects: 411
Study: 38849944

Group type: EXPERIMENTAL
Intervention: Intensive multidomain lifestyle intervention after 20 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wait-list usual care control group
Number of subjects: 51
Study: 38850034

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 38850200

Group type: EXPERIMENTAL
Intervention: Excellent bowel cleansing (20,934 individuals)
Number of subjects: 35710

Group type: EXPERIMENTAL
Intervention: Good bowel cleansing (6,580 individuals)
Number of subjects: 35710

Group type: EXPERIMENTAL
Intervention: Partly poor bowel cleansing (7,097 individuals)
Number of subjects: 35710

Group type: EXPERIMENTAL
Intervention: Poor bowel cleansing (1,099 individuals)
Number of subjects: 35710
Study: 38850311

Group type: EXPERIMENTAL
Intervention: Gallium-68-labeled FAP inhibitor 04
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38850317

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 235
Study: 38850402

Group type: EXPERIMENTAL
Intervention: Adjunctive cenobamate
Number of subjects: 40
Study: 38850466

Group type: EXPERIMENTAL
Intervention: 0-kg load
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 2-kg load
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 4-kg load
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Handheld weights
Number of subjects: 75

Group type: COMPARATOR
Intervention: Rotator cuff tears
Number of subjects: 75
Study: 38850687

Group type: EXPERIMENTAL
Intervention: Clinical adjudication process for evaluating infection status
Number of subjects: 955
Study: 38850996

Group type: EXPERIMENTAL
Intervention: Whey protein isolate ORS
Number of subjects: 14
Study: 38851019

Group type: EXPERIMENTAL
Intervention: Narrative videos and mini-VR games
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (tutorial including case-based discussions and role-play)
Number of subjects: 26
Study: 38851039

Group type: EXPERIMENTAL
Intervention: BOLSTER
Number of subjects: 77

Group type: COMPARATOR
Intervention: Enhanced Discharge Planning (EDP)
Number of subjects: 77
Study: 38851166

Group type: EXPERIMENTAL
Intervention: MK-8189 12 mg
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg (active control)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: MK-8189
Number of subjects: 224
Study: 38851203

Group type: EXPERIMENTAL
Intervention: First-line treatment (specific intervention details not provided)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 226
Study: 38851207

Group type: EXPERIMENTAL
Intervention: Ramucirumab (10 mg/kg intravenously) and Pembrolizumab (200 mg intravenously)
Number of subjects: 40
Study: 38851225

Group type: EXPERIMENTAL
Intervention: Malkia Klabu (Queen Club) intervention at ADDOs providing free contraceptives and oral HIV self-test kits, with a customer loyalty programme.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Malkia Klabu intervention
Number of subjects: 120
Study: 38851226

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 99
Study: 38851232

Group type: EXPERIMENTAL
Intervention: Vivomixx (450 billion colony-forming units per sachet) taken once daily until 1 week postpartum
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo taken once daily until 1 week postpartum
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Vivomixx
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 38851233

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring and oral glucose tolerance testing
Number of subjects: 2150
Study: 38851400

Group type: EXPERIMENTAL
Intervention: Loneliness assessment through questionnaires
Number of subjects: 2000
Study: 38851457

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 38851462

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg IV once daily for 7-14 days
Number of subjects: 525

Group type: COMPARATOR
Intervention: Levofloxacin IV once daily for 7-14 days
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Number of subjects: 525

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 525
Study: 38851554

Group type: EXPERIMENTAL
Intervention: Occupational Performance Coaching (OPC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 30
Study: 38851555

Group type: COMPARATOR
Intervention: Button hole technique (BG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: I-band technique (IG)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Exercises (EG)
Number of subjects: 108
Study: 38851634

Group type: EXPERIMENTAL
Intervention: Low-fat, high-protein, and high-fiber (LFHP) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-monounsaturated fatty acid (HMUFA) diet
Number of subjects: 0
Study: 38851666

Group type: EXPERIMENTAL
Intervention: Use of benzodiazepines for insomnia, delirium, and agitation in the elderly
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Use of hypnotics without a previous etiological diagnosis
Number of subjects: 33
Study: 38851676

Group type: EXPERIMENTAL
Intervention: Conventional heat-cured acrylic resin overdenture
Number of subjects: 16

Group type: COMPARATOR
Intervention: 3D-printed mandibular implant overdenture
Number of subjects: 16
Study: 38851706

Group type: EXPERIMENTAL
Intervention: Physical activity levels among PLWH
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Muscle index among PLWH
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Grip strength among PLWH
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT) performance among PLWH
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Physical activity level among PLWH
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Activity limitations among PLWH
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Depression levels among PLWH
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Social functioning scores among PLWH
Number of subjects: 300
Study: 38851710

Group type: EXPERIMENTAL
Intervention: Directional atherectomy plus drug-coated balloon (DCB)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 306
Study: 38851719

Group type: EXPERIMENTAL
Intervention: Learning Skills Together (LST) intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control condition focused on healthy living
Number of subjects: 200
Study: 38851732

Group type: EXPERIMENTAL
Intervention: Eight-session, group-based behavioral intervention delivered via videoconferencing.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist control group.
Number of subjects: 61
Study: 38852061

Group type: EXPERIMENTAL
Intervention: Mind/Body Program for Infertility (MBPI)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Fertility Support (FS)
Number of subjects: 168
Study: 38852114

Group type: EXPERIMENTAL
Intervention: Oral FTC/TDF
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Dapivirine ring
Number of subjects: 247
Study: 38852330

Group type: EXPERIMENTAL
Intervention: DBT + FFDM
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DBT + S2D
Number of subjects: 48

Group type: COMPARATOR
Intervention: FFDM
Number of subjects: 48

Group type: COMPARATOR
Intervention: Radiologists
Number of subjects: 48

Group type: COMPARATOR
Intervention: Radiographers
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Readers with 5+ years DBT experience
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Readers with less than 9 months DBT experience
Number of subjects: 48
Study: 38852379

Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with endocrine therapy (letrozole or fulvestrant)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 90
Study: 38852601

Group type: EXPERIMENTAL
Intervention: Neoadjuvant camrelizumab (200 mg IV on day 1) plus apatinib (250 mg orally from day 1-14, every 3 weeks for 3 months)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Neoadjuvant camrelizumab plus apatinib
Number of subjects: 53
Study: 38852600

Group type: EXPERIMENTAL
Intervention: Burr-hole drainage with subdural irrigation
Number of subjects: 589

Group type: COMPARATOR
Intervention: Burr-hole drainage without subdural irrigation
Number of subjects: 589
Study: 38852675

Group type: EXPERIMENTAL
Intervention: Upfront primary tumor resection (PTR) followed by systemic therapy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Systemic therapy without upfront PTR
Number of subjects: 204
Study: 38852760

Group type: EXPERIMENTAL
Intervention: Acamprosate treatment for three months
Number of subjects: 442
Study: 38852770

Group type: EXPERIMENTAL
Intervention: ASMD trial patients (before exposure to treatment)
Number of subjects: 18

Group type: COMPARATOR
Intervention: ASMD non-trial participants
Number of subjects: 18
Study: 38852906

Group type: EXPERIMENTAL
Intervention: Text messages sent to caregivers advising how to reschedule the missed appointment.
Number of subjects: 720

Group type: COMPARATOR
Intervention: Care-as-usual (control group).
Number of subjects: 720
Study: 38852934

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: PDE5i
Number of subjects: 0
Study: 38853036

Group type: EXPERIMENTAL
Intervention: RSVpreF
Number of subjects: 230
Study: 38853244

Group type: EXPERIMENTAL
Intervention: Liquid biopsy signature using circulating biomarkers
Number of subjects: 355

Group type: COMPARATOR
Intervention: Validation of multi-marker panel
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Establishment of a liquid biopsy biobank
Number of subjects: 355
Study: 38853251

Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management (GAM) intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Conventional care (control)
Number of subjects: 178
Study: 38853265

Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with chemotherapy (albumin-bound paclitaxel and carboplatin) for up to four cycles
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with chemotherapy
Number of subjects: 35
Study: 38853269

Group type: EXPERIMENTAL
Intervention: Multi-ingredient pre-workout dietary supplement (MIPS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 38853394

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg twice daily and Amoxicillin 750 mg four times daily (TA group)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg and Amoxicillin 750 mg four times daily (EA group)
Number of subjects: 368
Study: 38853420

Group type: EXPERIMENTAL
Intervention: Capillary blood ketone meter use (Intervention)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Pre-hospital fluid therapy (Intervention)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Pre-hospital fluid therapy (Control)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Ambulance capillary blood ketone meter use (Intervention)
Number of subjects: 388
Study: 38853438

Group type: EXPERIMENTAL
Intervention: MYTX-011
Number of subjects: 0
Study: 38853607

Group type: EXPERIMENTAL
Intervention: Letermovir
Number of subjects: 589

Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 589
Study: 38853614

Group type: EXPERIMENTAL
Intervention: altSonflex1-2-3
Number of subjects: 102

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 102
Study: 38853689

Group type: EXPERIMENTAL
Intervention: oHSV therapy (rQNestin34.5v.2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Depletion of IGF2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: oHSV-D11mt (modified IGF2R domain 11)
Number of subjects: 14
Study: 38853879

Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds (CMBs)
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: White matter hyperintensities (WMH)
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Combined diagnostic model including CVD biomarkers
Number of subjects: 1352
Study: 38853894

Group type: EXPERIMENTAL
Intervention: Participation in non-farming occupations for women
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Wealth quintile
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Non-short stature (nutritional status)
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Adequate interpregnancy interval (obstetric history)
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Prior pregnancy but no live birth (obstetric history)
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Symptoms of vaginal bleeding
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Awareness of the government's conditional cash transfer ANC program
Number of subjects: 31867

Group type: COMPARATOR
Intervention: Belonging to the lower Shudra caste
Number of subjects: 31867

Group type: COMPARATOR
Intervention: Maternal age below 18 or above 35
Number of subjects: 31867

Group type: COMPARATOR
Intervention: Preterm birth
Number of subjects: 31867

Group type: COMPARATOR
Intervention: Parity ≥ 1
Number of subjects: 31867

Group type: COMPARATOR
Intervention: Presence of hypertension during pregnancy
Number of subjects: 31867